Literature DB >> 26544697

Twenty years of boosting antiretroviral agents: where are we today?

Marta Boffito1, David Back, José M Gatell.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26544697     DOI： 10.1097/QAD.0000000000000800

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  4 in total

1.  Hepatitis D infection: from initial discovery to current investigational therapies.

Authors:  Ben L Da; Theo Heller; Christopher Koh
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-06-23

Review 2.  Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.

Authors:  Catia Marzolini; Daniel R Kuritzkes; Fiona Marra; Alison Boyle; Sara Gibbons; Charles Flexner; Anton Pozniak; Marta Boffito; Laura Waters; David Burger; David J Back; Saye Khoo
Journal:  Clin Pharmacol Ther       Date:  2022-05-14       Impact factor: 6.903

3.  The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects.

Authors:  Mark Johnson; Roxanne C Jewell; Amanda Peppercorn; Elizabeth Gould; Jianfeng Xu; Yu Lou; Matthew Davies; Sandra Baldwin; Allan R Tenorio; Matthew Burke; Jerry Jeffrey; Brian A Johns
Journal:  Pharmacol Res Perspect       Date:  2018-06-05

4.  Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Authors:  José M Gatell; Lambert Assoumou; Graeme Moyle; Laura Waters; Margaret Johnson; Pere Domingo; Julie Fox; Esteban Martinez; Hans-Jürgen Stellbrink; Giovanni Guaraldi; Mar Masia; Mark Gompels; Stephane De Wit; Eric Florence; Stefan Esser; François Raffi; Anton L Pozniak
Journal:  AIDS       Date:  2017-11-28       Impact factor: 4.177
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.